All In Biotech

Drug Trial Radar · NCT06834360

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Itepekimab in Adult Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 216 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

216

Actual

Start

Feb 6, 2025

Primary completion

Sep 24, 2026

Study completion Feb 17, 2027

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Regeneron Pharmaceuticals
First posted
Feb 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

EFC18419 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 3 study with 3 treatment groups. The purpose of the study is to evaluate the efficacy, safety and tolerability of 2 dosing regimens of itepekimab compared to placebo as add-on therapy to intranasal corticosteroids (INCS) in male and female participants with chronic rhinosinusitis with nasal polyps (CRSwNP) aged 18 years of age and older. Study details include: * The study duration per participant (4-week screening, 52-week treatment, 20-week safety follow-up) will be up to 76 weeks. For participants transitioning to the LTS18420 study, the study duration will be 56 weeks. * The treatment duration will be up to 52 weeks. * The number of visits will be 9 site visits and 20 phone/home visits.

Conditions

  • Chronic Rhinosinusitis With Nasal Polyps

Interventions

  • Itepekimab (SAR440340)Drug

    Pharmaceutical form: Solution for injection in prefilled syringe. Route of administration: Subcutaneous

  • PlaceboDrug

    Pharmaceutical form: Solution for injection in prefilled syringe. Route of administration: Subcutaneous

  • Mometasone furoate nasal spray (MFNS)Drug

    Pharmaceutical form: Solution for administration via spray pump. Route of administration: Intranasal spray

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in the endoscopic NPSTime frame: Baseline to Week 24
  2. Change from baseline in the NCSTime frame: Baseline to Week 24

Locations

111 sites in 23 countries. Site status is shown where the registry gives one.

  • Excel ENT of Alabama- Site Number : 8400052

    Birmingham, Alabama

  • Velocity Clinical Research - San Diego- Site Number : 8400041

    La Mesa, California

  • Cedars-Sinai Medical Center- Site Number : 8400030

    Los Angeles, California

  • One Of A Kind Clinical Research Center- Site Number : 8400034

    Napa, California

  • University of Florida - Jacksonville- Site Number : 8400053

    Jacksonville, Florida

  • Advanced Research Institute - New Port Richey- Site Number : 8400014

    New Port Richey, Florida

  • University of Illinois at Chicago- Site Number : 8400003

    Chicago, Illinois

  • Advanced ENT & Allergy - Louisville- Site Number : 8400007

    Louisville, Kentucky

  • Velocity Clinical Research - Lafayette- Site Number : 8400026

    Lafayette, Louisiana

  • Johns Hopkins Hospital- Site Number : 8400017

    Baltimore, Maryland

  • University of Cincinnati Medical Center- Site Number : 8400022

    Cincinnati, Ohio

  • Allergy, Asthma and Clinical Research- Site Number : 8400002

    Oklahoma City, Oklahoma

  • Thomas Jefferson University Hospital- Site Number : 8400044

    Philadelphia, Pennsylvania

  • Spartanburg-Greer ENT & Allergy- Site Number : 8400039

    Greer, South Carolina

  • Ear and Sinus Institute- Site Number : 8400048

    Fort Worth, Texas

  • Investigational Site Number : 0320002

    Buenos Aires, Argentina

  • Investigational Site Number : 0320001

    Buenos Aires, Argentina

  • Investigational Site Number : 0320004

    Corrientes, Argentina

  • Investigational Site Number : 0320003

    Mendoza, Argentina

  • Investigational Site Number : 0320005

    San Miguel de Tucumán, Tucumán Province, Argentina

  • Investigational Site Number : 0360003

    Bella Vista, New South Wales, Australia

  • Investigational Site Number : 0360002

    Brisbane, Queensland, Australia

  • Investigational Site Number : 0360001

    Spearwood, Western Australia, Australia

  • Investigational Site Number : 0560006

    Alken, Belgium

  • Investigational Site Number : 0560002

    Ghent, Belgium

  • Investigational Site Number : 0560001

    Leuven, Belgium

  • Investigational Site Number : 0560004

    Gesves, Namur, Belgium

  • Private Practice - Dr. Nelson Rosário- Site Number : 0760001

    Curitiba, Paraná, Brazil

  • Centro de Pesquisa Clínica de Marília - CPCLIM- Site Number : 0760002

    Marília, São Paulo, Brazil

  • Fundação Faculdade Regional de Medicina de São José do Rio Preto- Site Number : 0760005

    São José do Rio Preto, São Paulo, Brazil

  • Clinica de Alergia Martti Antila- Site Number : 0760003

    Sorocaba, São Paulo, Brazil

  • Investigational Site Number : 1240017

    Vancouver, British Columbia, Canada

  • Investigational Site Number : 1240019

    Burlington, Ontario, Canada

  • Investigational Site Number : 1240015

    Cambridge, Ontario, Canada

  • Investigational Site Number : 1240014

    Ottawa, Ontario, Canada

  • Investigational Site Number : 1240003

    Québec, Quebec, Canada

  • Investigational Site Number : 1240012

    Québec, Quebec, Canada

  • Investigational Site Number : 1520001

    Concepción, Biobio, Chile

  • Investigational Site Number : 1520004

    Talcahuano, Biobio, Chile

  • Investigational Site Number : 1520003

    Santiago, Reg Metropolitana de Santiago, Chile

Showing 40 of 111 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.